TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06263023

Intervention type: OTHER
Intervention: Sub-Normothermic Machine Preservation and Assessment
Description: Human kidneys from HTP deceased donors will be transported to the Sponsor's central preservation and assessment facility and placed onto a machine perfusion system in a sterile operating room for a brief period of Sub-Normothermic Machine Perfusion (SNMP). Basic parameters including internal renal resistance, oxygen, and electrolyte levels will be recorded using standard point-of-care hospital analyzers. Accepted kidneys will be transported to a participating transplant center using a portable oxygenated LifePort Hypothermic Machine Preservation (HMP) device.
Study: NCT05814367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blink® Tears eye drops in a multidose bottle
Description: Control
Study: NCT06729775

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Data report back preference by life span
Description: Data report back preference by life span.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Data report back preference by life span
Description: Data report back preference by life span.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Data report back preference by life span
Description: Data report back preference by life span.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Data report back preference by life span
Description: Data report back preference by life span.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Data report back preference by life span
Description: Data report back preference by life span.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Data report back preference by life span
Description: Data report back preference by life span.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Data report back preference by life span
Description: Data report back preference by life span.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Data report back preference by life span
Description: Data report back preference by life span.
Study: NCT06731062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EF192A
Description: EF192A will be applied through a patch test to the participants' backs for 3 consecutive weeks, with 3 weekly applications. Afterwards, there will be a rest period of between 10 and 15 days. EF192A will be reapplied to the participants' back in a naive area and removed after 48 hours.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Saline solution
Description: The saline solution will be applied via patch test to the participants' backs for 3 consecutive weeks, with 3 weekly applications. Afterwards, there will be a rest period of between 10 and 15 days. The saline solution will be applied again to the participants' back in a naive area and removed after 48 hours.
Study: NCT06130436

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Conditioning Twice Daily
Description: Remote Ischemic Conditioning (at the time points of 30 min before anesthesia, 30 min after surgery, the morning of the postoperative day 1, the afternoon of the postoperative day 1, the morning of the postoperative day 2, the afternoon of the postoperative day 2): Three cycles (30 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff. The cuff pressure will be 200 mmHg.
Study: NCT05221021

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal estrogen
Description: 0.01% estradiol cream 1/2 gram applied vaginally once nightly for two weeks then three times per week with once daily placebo oral pill

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron 50 MG [Myrbetriq]
Description: 50mg oral Mirabegron once daily
Study: NCT06559358

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrical stimulation
Description: A two-channel portable electrical stimulation unit (BTL-4620, Czech Republic).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrical stimulation
Description: A two-channel portable electrical stimulation unit (BTL-4620, Czech Republic).
Study: NCT05442632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag
Description: The patients received Hetrombopag 5mg orally d1-14 days, surgery will be conducted at d6-14 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The patients received Placebo 5mg orally d1-14 days, surgery will be conducted at d6-14 day
Study: NCT05298839

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of core muscle endurance, hand grip strength, upper extremity functional performance, reaction time, agility performance and 3 minutes step test
Description: Core muscle endurance was evaluated with extensor muscle endurance test, flexor muscle endurance test and lateral muscle endurance test.~Hand Grip Strength was evaluated with Jamar hand dynamometer. Upper extremity functional performance was evaluated with health ball throwing test.~Reaction time was evaluated with Fitlight Trainer. Agility performance was evaluated with Pro-agility test. Cardiovascular endurance was evaluated with the 3-minute step test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of core muscle endurance, hand grip strength, upper extremity functional performance, reaction time, agility performance and 3 minutes step test
Description: Core muscle endurance was evaluated with extensor muscle endurance test, flexor muscle endurance test and lateral muscle endurance test.~Hand Grip Strength was evaluated with Jamar hand dynamometer. Upper extremity functional performance was evaluated with health ball throwing test.~Reaction time was evaluated with Fitlight Trainer. Agility performance was evaluated with Pro-agility test. Cardiovascular endurance was evaluated with the 3-minute step test.
Study: NCT06559358

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: electrical stimulation
Description: A two-channel portable electrical stimulation unit (BTL-4620, Czech Republic).
Study: NCT05943665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: medication and therapy combined
Study: NCT05650775

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concerta
Description: 3-week trial of oral methylphenidate extended release

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adderall-XR
Description: 3-week trial of oral mixed amphetamine salts, extended release, administered only to children who do not show at least 30% improvement during the Concerta/Methylphenidate trial.
Study: NCT05190068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-760
Description: HMPL-760 was administered continuously as a single agent orally every day in sequential 28-day cycles.
Study: NCT06044090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Participants will take 2 pills of 100 mg totaling a 200 mg dose of minocycline per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Participants will take 2 pills of 100 mg totaling a 200 mg dose of minocycline per day.
Study: NCT05814367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blink® Tears eye drops in a multidose bottle
Description: Control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preservative-free investigational lubricating eye drops in a Novelia® eyedropper
Description: Test
Study: NCT05157425

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food Supplement
Description: Probiotic multistrain formulation containing Lactiplantibacillus plantarum CECT30292, CECT7484, CECT7485 and P. acidilactici CECT7483 for 28 days, starting the same day of influenza vaccination

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One maltodextrin-containing capsule/day for 28 days, starting the same day of influenza vaccination
Study: NCT04705467

Intervention type: DEVICE
Group type: OTHER
Intervention: Gynecological brachytherapy
Description: Management of gynecological malignancies is done through brachytherapy treatment, which involves the delivery of radiation via radioactive sources that are placed into or in close proximity to the tumour.
Study: NCT06276387

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Program
Description: Participants will receive eight weekly 2.5-hour group sessions and one day-long silent retreat, delivered online. Intervention content will include the MBSR program, which has been extensively studied with many different chronic conditions, and augmentations for individuals with rheumatic diseases. Each MBSR session will include meditation practices (e.g., sitting meditation, body scan, gentle hatha yoga, walking meditation, mindfulness of daily activities, awareness of pleasant and unpleasant events) and review of home practice. Participants will complete daily home practices for about 45 minutes per day and log their practice.
Study: NCT06044090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive 2 placebo tablets matching the Minocycline tablets daily for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive 2 placebo tablets matching the Minocycline tablets daily for 5 days.
Study: NCT05851391

Intervention type: DRUG
Group type: OTHER
Intervention: Burst Suppression EEG Target Intravenous Anesthesia
Description: The objective of the burst suppression EEG target is to stop seizures by titrating the anesthetic infusion to suppress most of the EEG background (\>50% suppressed/attenuated). After this 24-hour period, this target would be continued for 24 hours. The anesthetic will then be tapered under EEG monitoring. In case of PCARSE recurrence, the intervention with the same target will be re-initiated for another cycle of 24 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Seizure Suppression EEG Target Intravenous Anesthesia
Description: is to stop seizures by titrating the anesthetic infusion without suppressing most of the EEG background. This target would be continued for 24 hours. After this 24-hours period, this target would be continued for 24 hours. The anesthetic will then be tapered under EEG monitoring. In case of PCARSE recurrence, the intervention with the same target will be re-initiated for another cycle of 24 hours.
Study: NCT05080322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Nasal 50 Mcg/Inh Nasal Spray, Azelastine Nasal 140 Mcg/Inh Nasal Spray
Description: on-demand INS (Fluticasone) combined with nasal spray AH1(Azelastine)
Study: NCT05814367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preservative-free investigational lubricating eye drops in a Novelia® eyedropper
Description: Test
Study: NCT04147949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-101
Description: Oral capsules taken twice daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules taken twice a day for 14 days
Study: NCT05038254

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care telemedicine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive standard of care telemedicine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive standard of care telemedicine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient Monitoring
Description: Undergo remote monitoring

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient Monitoring
Description: Undergo remote monitoring

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05926583

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AAV5-hRKp.RPGR
Description: AAV5-hRKp.RPGR will be administered by subretinal injection using a standardized surgical procedure.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AAV5-hRKp.RPGR
Description: AAV5-hRKp.RPGR will be administered by subretinal injection using a standardized surgical procedure.
Study: NCT05844384

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nanodropper
Description: Nanodropper delivers 1/5 of eye drop volume compared to regular droppers

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regular dropper
Description: Delivers full eye drop volume
Study: NCT05182164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Association of pembrolizumab + cabozantinib
Description: A treatment cycle consists of 3 weeks. Pembrolizumab will be administered intraveinously on day 1 every 3 weeks (200 mg).~Cabozantinib will be administered per os, once daily (40 mg), and given on a continuous basis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Association of pembrolizumab + cabozantinib
Description: A treatment cycle consists of 3 weeks. Pembrolizumab will be administered intraveinously on day 1 every 3 weeks (200 mg).~Cabozantinib will be administered per os, once daily (40 mg), and given on a continuous basis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Association of pembrolizumab + cabozantinib
Description: A treatment cycle consists of 3 weeks. Pembrolizumab will be administered intraveinously on day 1 every 3 weeks (200 mg).~Cabozantinib will be administered per os, once daily (40 mg), and given on a continuous basis.
Study: NCT04767425

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: • 3D image-based cervical cancer brachytherapy will be delivered as 4 sessions x 7 Gy High Dose Rate (HDR) brachytherapy
Study: NCT04722718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab+Apatinib+Albumin-Bound Paclitaxel(Nab-Paclitaxel)+Carboplatin
Description: Sintilimab:200mg,ivgtt,d1,21days/cycle;Apatinib:250mg po,d1-14days,21days/cycle;Albumin-Bound Paclitaxel(Nab-Paclitaxel):125mg/m2,ivgtt,d1,d8,21days/cycle;Carboplatin:AUC=1.5,ivgtt,d1,d8, 21days/cycle.Monitoring of blood routine, biochemical and urine routine, electrocardiogram, and record the patient's drug-related adverse reactions every cycle,according to the curative effect of patients, compliance and tolerance, neoadjuvant therapy 6 cycles,every 2 cycles to evaluate curative effect (ultrasonic, breast X-ray CT, bone scan, brain, lungs, assessment and breast MRI imaging).
Study: NCT04758793

Intervention type: OTHER
Group type: OTHER
Intervention: blood samples
Description: 3 citrated tubes and 3 EDTA tubes

Intervention type: OTHER
Group type: OTHER
Intervention: blood samples
Description: 3 citrated tubes and 3 EDTA tubes

Intervention type: OTHER
Group type: OTHER
Intervention: blood samples
Description: 3 citrated tubes and 3 EDTA tubes

Intervention type: OTHER
Group type: OTHER
Intervention: blood samples
Description: 3 citrated tubes and 3 EDTA tubes

Intervention type: OTHER
Group type: OTHER
Intervention: biopsy of abdominal paroie
Description: a muscle biopsy will be performed on the incision area

Intervention type: OTHER
Group type: OTHER
Intervention: biopsy of abdominal paroie
Description: a muscle biopsy will be performed on the incision area

Intervention type: OTHER
Group type: OTHER
Intervention: biopsy of abdominal paroie
Description: a muscle biopsy will be performed on the incision area

Intervention type: OTHER
Group type: OTHER
Intervention: biopsy of abdominal paroie
Description: a muscle biopsy will be performed on the incision area
Study: NCT05080322

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Nasal 50 Mcg/Inh Nasal Spray
Description: on-demand or maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Nasal 50 Mcg/Inh Nasal Spray
Description: on-demand or maintenance
Study: NCT04076735

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal femoral replacement
Description: The distal portion of the femur (up to two thirds) is excised and replaced by a endoprosthesis incorporating a hinged total knee replacement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Fixation (ORIF)
Description: A trained orthopaedic surgeon uses open or minimally invasive reduction techniques and achieves stable fixation with internal fixation devices (plates/screws or intramedullary nail) to restore structural integrity and alignment of the distal femur
Study: NCT05185856

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: 15 minutes eccentric cycling
Description: The exposure to eccentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 15 minutes eccentric cycling
Description: The exposure to eccentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: 15 minutes concentric (normal) cycling
Description: The exposure to concentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 15 minutes concentric (normal) cycling
Description: The exposure to concentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
Study: NCT06101628

Intervention type: OTHER
Group type: OTHER
Intervention: Gel nail application
Description: The middle finger of the left hand of each participant will be the experimental group and the little finger will be the control group. After the gel nail is applied to the middle finger of the left hand, SpO2 and pulse values will be measured by pulse oximetry from the left hand middle finger and little finger of the participant
Study: NCT04581603

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: CBT-I is conducted weekly for eight sessions during which the subjects meet individual with the study clinician for 45 minutes on the first session and for 30 minutes for sessions 2-8. Session 1 serves as an orientation and the onset of Sleep Restriction Therapy. Sessions 2 \& 3 deliver the three main components that include, Sleep Restriction Therapy, Stimulus control, and Sleep Hygiene. All the sessions excluding the last two sessions are dedicated to the titration of total sleep time and to ensure patient adherence. The fifth session is used to deliver a specific form of cognitive therapy. The final session is used to engage the patient in a relapse-prevention didactic (i.e., to review how insomnia becomes chronic and strategies that abort an extended episode of insomnia). The subject will return on week 9 to complete the post-intervention visit after 8 weeks of behavioral sleep treatment.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sleep Hygiene Education
Description: This non-active control arm of behavioral sleep intervention consists of psychoeducation on sleep hygiene, sleep-related disturbances, and the effects of stress on sleep that will be delivered weekly for 8 weeks, for a time duration that is identical to the CBT-I sessions. The effect of stress on sleep is a commonly used control condition in insomnia clinical trials. SHE is preferred to a monitor-only condition as it will control for contact with the therapist and elapsed time during sessions. The subject will return on week 9 to complete the post-intervention visit after 8 weeks of behavioral sleep treatment.
Study: NCT06351150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin II Injection
Description: 1、Angiotensin II injection is a naturally occurring octapeptide hormone in the human renin angiotensin aldosterone system (RAAS). It is the main effector molecule of the RAAS system and one of the strongest known vasoconstrictors, involved in neurohumoral regulation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride injection
Description: 0.9% sodium chloride injection, not containing active ingredients.
Study: NCT06248619

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Teprotumumab
Description: SC injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC injection
Study: NCT05400330

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LX1001
Description: Gene therapy
Study: NCT06460129

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brugger's Exercises
Description: 1. The participant will sit upright and wrap an elastic resistance band around each hand, leaving the palms open. They will perform thumb and finger abduction and extension, wrist extension, and forearm supination. This will be followed by scapular retraction with shoulder external rotation, elbow extension, shoulder abduction, and extension, holding this position for 10 seconds.~2. In both sitting and standing positions, the participant will sit at the edge of a seat, naturally lifting the sternum, with legs spread at a 45-degree angle and feet slightly turned out. Shoulders should be relaxed, chin tucked, and elbows fully extended. The participant will keep their shoulders down, imagining the scapulae pressing together and downward into a V shape, with thumbs turned out, palms up, and fingers spread. This position is held for 10 seconds.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kendal Exercise
Description: 1. In a supine position, the participant will place a towel around their neck. With their head on the floor, they will tuck their chin and use the towel to apply gentle resistance, holding for 10 seconds to strengthen the deep flexor muscles of the cervical spine.~2. In a prone position, the participant will point their thumbs toward the ceiling and extend their arms fully while leaning forward, then return to the starting position. They will then extend their arms horizontally and hold for 10 seconds.~3. The participant will place both hands on the back of their head, lift their elbows upward, pull them back, and simultaneously spread their arms out to the side. This position will be held for 10 seconds before returning to the starting position.
Study: NCT05095740

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: Repetitive transcranial magnetic stimulation used to regulate the contribution of the laryngeal motor cortex to voice production and laryngeal motor muscle activation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS
Description: Repetitive transcranial magnetic stimulation used to a cortical area not associated with change in outcomes at an intensity substantially lower than that of the established threshold.